| Line 13: |
Line 13: |
| | | | |
| | Possible mammary tumours include: | | Possible mammary tumours include: |
| − | :'''Benign''': Adenoma/fibroadenoma | + | :'''Benign''': [[adenoma]]/fibroadenoma, benign mesenchymal tumour, benign mixed tumour |
| | + | :'''Malignant''': [[carcinoma]] (solid, tubular, papillary, inflammatory), [[sarcoma]], carcinosarcoma, [[adenocarcinoma]] |
| | | | |
| − | ::Benign mesenchymal tumour
| + | ==Clinical Presentation== |
| − | | |
| − | ::Benign mixed tumour
| |
| − | | |
| − | :'''Malignant''': Carcinoma: solid, tubular, papillary, inflammatory
| |
| − | | |
| − | ::Sarcoma
| |
| − | | |
| − | ::Carcinosarcoma
| |
| − | | |
| − | ::Adenocarcinoma
| |
| − | | |
| − | ==Clinical presentation== | |
| | The animal will present with a history of the owner noticing a '''lump''', or it may be discovered during routing physical examination. It is rare for the animal to present with signs referable to metastases such as coughing or lameness. | | The animal will present with a history of the owner noticing a '''lump''', or it may be discovered during routing physical examination. It is rare for the animal to present with signs referable to metastases such as coughing or lameness. |
| | | | |
| Line 43: |
Line 32: |
| | | | |
| | ==Diagnosis== | | ==Diagnosis== |
| − | Mammary neoplasms cannot be diagnosed visually. | + | Mammary neoplasms cannot be diagnosed visually. The aim is to obtain a diagnosis and to stage the disease using the '''TNM system''': |
| | + | :<u>Tumour size</u>: T1 <3cm, T2 3-5cm, T3 >5cm |
| | + | :<u>Regional lymph node</u>: N0 no metastasis, N1 metastasis |
| | + | :<u>Distant metastasis</u>: M0 not present, M1 present |
| | | | |
| − | The aim is to obtain a diagnosis and to stage the disease using the '''TNM system''':
| + | '''Haematology and biochemistry''' should be performed to make sure geriatric patients are safe to anaesthetise. |
| | | | |
| − | <u>Tumour size</u>: T1 <3cm, T2 3-5cm, T3 >5cm
| + | '''Radiography''' of the thorax and abdomen to check for distant metastases is recommended. |
| − | | |
| − | <u>Regional lymph node</u>: N0 no metastasis, N1 metastasis
| |
| − | | |
| − | <u>Distant metastasis</u>: M0 not present, M1 present
| |
| − | | |
| − | | |
| − | '''Haematology and biochemistry''' should be performed to make sure geriatric patients are safe to anaesthetise
| |
| − | | |
| − | '''Radiography''' of the thorax and abdomen to check for distant metastases | |
| − | | |
| − | '''Abdominal ultrasound''' to check the sublumbar and inguinal lymph nodes.
| |
| | | | |
| | + | '''Abdominal ultrasound''' to check the sublumbar and inguinal lymph nodes is also useful. |
| | | | |
| | '''Fine needle aspiration and cytological analysis''' of the mass is an essential tool: it may reveal cells with criteria for malignancy, with distinct nucleoli, high nuclear-cytoplasmic ratio and moderate anisocytosis and anisokaryosis. | | '''Fine needle aspiration and cytological analysis''' of the mass is an essential tool: it may reveal cells with criteria for malignancy, with distinct nucleoli, high nuclear-cytoplasmic ratio and moderate anisocytosis and anisokaryosis. |
| Line 68: |
Line 50: |
| | | | |
| | '''Immunohistochemistry''' can be performed to determine the presence of hormone receptors in the tumour, but this is an expensive test which does not really alter the treatment plan. | | '''Immunohistochemistry''' can be performed to determine the presence of hormone receptors in the tumour, but this is an expensive test which does not really alter the treatment plan. |
| − |
| |
| | | | |
| | Other diseases which may '''mimic mammary masses''' and which should be ruled out include: | | Other diseases which may '''mimic mammary masses''' and which should be ruled out include: |
| Line 93: |
Line 74: |
| | ==Prognosis== | | ==Prognosis== |
| | In '''dogs''', prognostic factors include: | | In '''dogs''', prognostic factors include: |
| − | | + | :'''Tumour size''': <3cm 30% recurrence, >3cm 85% recurrence |
| − | '''Tumour size''': <3cm 30% recurrence, >3cm 85% recurrence | + | :'''Histologic type''': sarcomas are worse than carcinomas or mixed types |
| − | | + | :'''Grade/differentiation''': 90% mortality at 2 years if the cells are poorly differentiated, 24% mortality at 2 years if the cells are well differentiated. |
| − | '''Histologic type''': sarcomas are worse than carcinomas or mixed types | + | :'''Lymph node involvement''': if present, there is 80% recurrence. |
| − | | + | :'''Distant metastases''' have a poorer prognosis |
| − | '''Grade/differentiation''': 90% mortality at 2 years if the cells are poorly differentiated, 24% mortality at 2 years if the cells are well differentiated. | + | :'''Presence of progesterone/oestrogen receptors''' holds a better prognosis. |
| − | | |
| − | '''Lymph node involvement''': if present, there is 80% recurrence. | |
| − | | |
| − | '''Distant metastases''' have a poorer prognosis | |
| − | | |
| − | '''Presence of progesterone/oestrogen receptors''' holds a better prognosis. | |
| | | | |
| | There is no evidence that site or number of tumours is a prognostic indicator. | | There is no evidence that site or number of tumours is a prognostic indicator. |
| − |
| |
| | | | |
| | '''Inflammatory carcinomas''' have a grave prognosis with <4 weeks survival time. '''Malignant tumours''' incompletely excised hold a 75% mortality within the year. Dogs with malignant tumours completely excised and with no evidence of metastases are expected to live 1-2 years. Complete excision of '''benign tumours''' is curative. | | '''Inflammatory carcinomas''' have a grave prognosis with <4 weeks survival time. '''Malignant tumours''' incompletely excised hold a 75% mortality within the year. Dogs with malignant tumours completely excised and with no evidence of metastases are expected to live 1-2 years. Complete excision of '''benign tumours''' is curative. |
| − |
| |
| | | | |
| | In '''cats''', prognostic factors include: | | In '''cats''', prognostic factors include: |
| − | | + | :'''Tumour size''': >3cm medial survival time <6 months, <2cm median survival time 3 years. |
| − | '''Tumour size''': >3cm medial survival time <6 months, <2cm median survival time 3 years. | + | :'''Extent of surgery''': there is 66% recurrence if local surgery rather than radical mastectomy is performed |
| − | | + | :'''Histologic grading''': well differentiated tumours with no evidence of lymphatic invasion have a better prognosis. |
| − | '''Extent of surgery''': there is 66% recurrence if local surgery rather than radical mastectomy is performed | |
| − | | |
| − | '''Histologic grading''': well differentiated tumours with no evidence of lymphatic invasion have a better prognosis. | |
| − | | |
| | | | |
| | The overall median survival time is <1 year and the disease hold a '''poor prognosis overall in cats'''. | | The overall median survival time is <1 year and the disease hold a '''poor prognosis overall in cats'''. |
| Line 129: |
Line 98: |
| | | | |
| | In cats the relative risk if spayed '''before 1 year''' is 0.6% compared to intact cats. | | In cats the relative risk if spayed '''before 1 year''' is 0.6% compared to intact cats. |
| | + | |
| | + | <big><b>Also see [[Mammary Neoplasia - Rat]]</b></big> |
| | | | |
| | ==References== | | ==References== |
| Line 140: |
Line 111: |
| | | | |
| | | | |
| − | [[Category:To Do - Helen]]
| + | {{review}} |
| − | [[Category:To Do - Review]]
| |
| | | | |
| | + | [[Category:Expert Review - Small Animal]] |
| | [[Category:Neoplasia]] | | [[Category:Neoplasia]] |
| | [[Category:Mammary Gland - Pathology]] | | [[Category:Mammary Gland - Pathology]] |
| − | [[Category:To Do - Reproductive]] | + | [[Category:Reproductive Diseases - Dog]] |
| | + | [[Category:Reproductive Diseases - Cat]] |
| | + | [[Category:Dermatological Diseases - Cat]] |
| | + | [[Category:Dermatological Diseases - Dog]] |